Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation.

IF 2.3 4区医学 Q2 PERIPHERAL VASCULAR DISEASE

Blood Pressure Pub Date : 2017-02-01 Epub Date: 2016-05-19 DOI:10.1080/08037051.2016.1182856

Christos Chatzikyrkou, Jenny Eichler, Annika Karch, Christian Clajus, Florian Gunnar Scurt, Wolf Ramackers, Frank Lehner, Jan Menne, Hermann Haller, Peter R Mertens, Mario Schiffer

{"title":"Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation.","authors":"Christos Chatzikyrkou, Jenny Eichler, Annika Karch, Christian Clajus, Florian Gunnar Scurt, Wolf Ramackers, Frank Lehner, Jan Menne, Hermann Haller, Peter R Mertens, Mario Schiffer","doi":"10.1080/08037051.2016.1182856","DOIUrl":null,"url":null,"abstract":"Background: The efficacy and safety of renin angiotensin aldosterone system blockers (RAASB's) if introduced immediately after renal transplantation have not been extensively investigated.Methods: The medical charts of 142 kidney transplant recipients who received a RAASB in the early postoperative period and of 114 matched controls were analyzed. The RAASB was given primarily for blood pressure control.Results: 117 patients continued to receive and 50 controls remained continuously free of the RAASB in the first year. The RAASB was added on average at postoperative day 8 and the mean duration of follow-up was 5.4 years. Systolic, blood pressure at treatment initiation was increased in the RAASB group (150 ± 17 vs. 141 ± 16, p < 0.001). At discharge from hospital and during follow-up blood pressure was similar in both groups, without differences in GFR, potassium and proteinuria. The endpoints \"graft failure\" and \"graft failure or death from any cause\" were significantly better in patients treated with RAASB's (p = 0.03 and p = 0.04, respectively). The treatment effects in the RAASB group persisted even after adjustment for demographic parameters, immunological risk factors, peritransplant risk factors, duration of dialysis prior to transplantation and medical comorbidities.Conclusions: Thus, RAASB's can be used effectively and safely to treat hypertension in the early postoperative period after kidney transplantation and are renoprotective in the long term.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1182856","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Pressure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08037051.2016.1182856","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/5/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 5

Abstract

Background: The efficacy and safety of renin angiotensin aldosterone system blockers (RAASB's) if introduced immediately after renal transplantation have not been extensively investigated.

Methods: The medical charts of 142 kidney transplant recipients who received a RAASB in the early postoperative period and of 114 matched controls were analyzed. The RAASB was given primarily for blood pressure control.

Results: 117 patients continued to receive and 50 controls remained continuously free of the RAASB in the first year. The RAASB was added on average at postoperative day 8 and the mean duration of follow-up was 5.4 years. Systolic, blood pressure at treatment initiation was increased in the RAASB group (150 ± 17 vs. 141 ± 16, p < 0.001). At discharge from hospital and during follow-up blood pressure was similar in both groups, without differences in GFR, potassium and proteinuria. The endpoints "graft failure" and "graft failure or death from any cause" were significantly better in patients treated with RAASB's (p = 0.03 and p = 0.04, respectively). The treatment effects in the RAASB group persisted even after adjustment for demographic parameters, immunological risk factors, peritransplant risk factors, duration of dialysis prior to transplantation and medical comorbidities.

Conclusions: Thus, RAASB's can be used effectively and safely to treat hypertension in the early postoperative period after kidney transplantation and are renoprotective in the long term.

查看原文本刊更多论文

肾移植后立即使用RAAS阻滞剂的短期和长期影响。

背景:肾素血管紧张素醛固酮系统阻滞剂(RAASB’s)在肾移植后立即应用的有效性和安全性尚未得到广泛的研究。方法:分析142例肾移植术后早期行RAASB的患者及114例对照者的病历资料。RAASB主要用于控制血压。结果:117名患者在第一年继续接受RAASB治疗，50名对照组持续无RAASB治疗。术后第8天平均增加RAASB，平均随访时间5.4年。RAASB组治疗开始时收缩压升高(150±17比141±16,p)。结论:RAASB可有效、安全地治疗肾移植术后早期高血压，并具有长期的肾保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Pressure 医学-外周血管病

CiteScore

3.00

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management. Features include: • Physiology and pathophysiology of blood pressure regulation • Primary and secondary hypertension • Cerebrovascular and cardiovascular complications of hypertension • Detection, treatment and follow-up of hypertension • Non pharmacological and pharmacological management • Large outcome trials in hypertension.